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Background: Oral immunotherapy (OIT) has shown promise in inducing desensitization for food allergy. However,
there are safety concerns regarding the frequency and severity of adverse events during food OIT.
Objective: To evaluate the effect of Ketotifen premedication on adverse reactions during peanut OIT.
Methods: A randomized single blind placebo controlled pilot study was performed. Peanut OIT was performed
using a previously published protocol. Ketotifen was up-titrated to 2 mg twice daily over two weeks (week −2 to 0),
followed by a peanut OIT initial escalation day (day 1). Ketotifen was administered from week 0–4 of peanut OIT;
reactions to peanut OIT doses were recorded by clinic staff and subject diary.
Results: Six subjects (median age 10 years, peanut IgE >100kUA/L) were enrolled, 4 randomized to Ketotifen, 2 to
placebo. The most common side effect of Ketotifen was fatigue (9% during up-titration). The rate of reaction per
peanut OIT dose was lower for subjects on ketotifen (K) compared to placebo (P) during initial escalation on day 1
(K: 22% (8/36) vs. P: 67% (12/18)); week 0–4 build-up doses (K: 75% (3/4) vs. P: 100% (2/2)); and week 0–4 home
doses (K: 50% (54/108) vs. P: 82% (27/33)). The rate of gastrointestinal symptoms per peanut OIT dose was also
lower for subjects on ketotifen during initial escalation on day 1 (K: 17% (6/36) vs. P: 61% (11/18)); week 0–4
build-up doses (K: 75% (3/4) vs P: 100% (2/2)); and week 0–4 home doses (K: 46% (50/108) vs. P: 82% (27/33)).
Conclusions: Ketotifen premedication is well tolerated and reduces the rate of gastrointestinal symptoms during
peanut OIT. These findings require confirmation in a larger study of Ketotifen premedication used throughout
peanut OIT.
Trial registration: Clinical Trials number: NCT0162515
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Peanut allergy is a significant health concern in North
America: an estimated 1.4% of children in the United
States have a diagnosis of peanut allergy, and the preva-
lence is rising [1]. Peanut allergy generally presents in
childhood, is persistent in approximately 80% of cases,
[2,3] and is the most commonly implicated food allergy
in fatal anaphylactic reactions [4]. There is currently no
cure for peanut allergy. Management of peanut allergy
involves strict avoidance of peanut and carriage of self-* Correspondence: gsussman@rogers.com
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unless otherwise stated.injectable epinephrine for emergency treatment, should
an accidental ingestion occur. The ongoing need for dili-
gent avoidance and the fear of accidental ingestion has a
significant impact on patients’ quality of life [5].
The development of active approaches to treatment of
peanut allergy is underway. Early study of subcutaneous
immunotherapy in food allergy was stopped due to fre-
quent systemic reactions [6,7]. Oral immunotherapy for
food allergy is now being evaluated. Early studies of oral
immunotherapy (OIT) for peanut allergy have shown
promise in inducing desensitization [8,9]. However, further
investigation into the safety and efficacy profile is needed
before peanut OIT can be recommended for clinical use
[8,10]. Frequent and sometimes severe adverse allergictd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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cent systematic review, adverse reactions were reported in
all six studies examined, with the highest frequency of
reactions during periods of rapid dose escalation [8]. A
study of the safety profile of peanut OIT reported that
93% of patients experienced adverse reactions during
the initial peanut dose escalation day, involving predomin-
antly gastrointestinal, upper respiratory, and cutaneous
symptoms [11].
The issue of adverse reactions during immunotherapy
is not limited to peanut OIT. Immunotherapy for hymen-
optera venom allergy is highly effective, but associated
with frequent and occasionally severe adverse allergic re-
actions, particularly during the dose escalation phase. Use
of antihistamine premedication has been demonstrated to
reduce local and systemic reactions during venom im-
munotherapy, without affecting the efficacy of venom
immunotherapy [12,13]. The mechanism is thought to
involve alteration in histamine receptor expression on
allergen-specific T cells and altered cytokine profiles
observed in patients receiving premedication with anti-
histamines [13].
Ketotifen is a benzocycloheptathiophene derivative
with histamine receptor antagonist and mast cell stabil-
izing properties [14]. Clinically, ketotifen has been pre-
viously used for conditions ranging from childhood
asthma to eosinophilic gastroenteritis, urticaria pig-
mentosa, and cold urticaria [15-18]. Ketotifen has dem-
onstrated efficacy in treatment of allergic conjunctivitis,
although is less effective and comfortable compared to
ophthalmic olopatadine [19,20]. Ketotifen was also in-
vestigated for use in pediatric systemic mastocytosis,
but in comparison to hydroxyzine, offered no symptom-
atic benefit or change in plasma or 24-hour urine hista-
mine levels [21]. At present, ketotifen is indicated for
treatment of allergic conjunctivitis, and is available in
ophthalmic formulation only in the USA. Oral ketotifen
is available in Canada, and is considered a safe medica-
tion, the dose of which is limited by the sedating side
effects [22].
The aim of this study was to evaluate the use of pre-
medication in the setting of oral immunotherapy for pea-
nut allergy. Ketotifen was selected as the premedication
agent for its dual antihistamine and mast cell stabilizing
properties; established safety record; and, to examine
whether it may mitigate gastrointestinal symptoms fre-
quently observed during food oral immunotherapy given
its previously documented benefit in eosinophilic gastro-
enteritis. Using a previously published protocol for peanut
OIT [9,23] we conducted a small randomized, single-
blind, placebo controlled pilot study examining the rate
and severity of adverse reactions during peanut OIT with
ketotifen premedication during the initial four weeks of
peanut dose escalation.Methods
Subject recruitment and selection
Forty subjects were screened from this Allergy & Immun-
ology clinic. The accrual objective was six subjects for this
pilot study. Inclusion criteria included: age ≥ 8 years; peanut
skin prick test ≥ 3 mm, and peanut specific IgE >7 kUA/L
(CAP-FEIA, Phadia AB; Pharmacia, Inc, Uppsala, Sweden);
and convincing history of reaction within 60 minutes of
peanut consumption. Exclusion criteria were: moderate/se-
vere persistent asthma; current requirement for greater
than medium daily doses of inhaled corticosteroids, as de-
fined by the NHLBI guidelines; poorly controlled or persist-
ent atopic dermatitis; diabetes; known oat or wheat allergy
(due to potential cross-contamination); severe anaphylaxis
to peanut as defined by hypoxia, hypotension, or neuro-
logical compromise; inability to discontinue antihista-
mines for skin testing; history of epilepsy or seizures;
current participation in an investigational drug study; or
participation in an interventional treatment for food al-
lergy within the previous 12 months.
This study was performed with approval by Canadian
Shield Ethics Board, and written informed consent was
obtained from subjects and their guardian. Other than
peanut OIT, subjects continued strict avoidance of pea-
nut in their diet prior and during the study.
Randomization
Randomization was performed by use of blinded envelopes
in a ratio of 2:1 for ketotifen: placebo. Randomization
allocation was stored in a locked database accessible only
by clinical staff. Clinical staff were aware of assigned inter-
vention; subjects remained blinded until completion of the
study.
Study design
This was a single-blind placebo-controlled study (Figure 1).
During the initial visit, a baseline history, physical exam,
and blood draw for peanut specific IgE was performed.
After randomization subjects underwent a 2 week up-
titration of ketotifen dosing or placebo, up to a maximum
dose of 2 mg ketotifen twice daily. This dose was approved
by Health Canada and chosen to maximize efficacy of the
premedication protocol. This was followed by an initial
day escalation phase for peanut OIT, long term build-up
phase over 44 weeks, and maintenance phase for 4 weeks
at the highest tolerated dose, using a previously described
protocol modified for use in the outpatient clinic [9,23].
The ketotifen dose was tapered and then discontinued at
4 weeks after the initial escalation day based on IRB ap-
proval. The primary endpoint for this study was the rate
and severity of adverse reactions occurring on the initial
escalation day in the ketotifen group compared to the pla-
cebo group. The secondary endpoints for the study in-
cluded: the rate and severity of gastrointestinal adverse
Figure 1 Study design.
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the OIT protocol, and the rate of adverse reactions leading
to study withdrawal in the ketotifen and placebo groups,
respectively.
Skin prick testing
Skin prick testing was performed prior to enrollment
with commercial peanut extract, histamine and saline
controls (Alk-Abello, Ontario, Canada). Skin tests were
read after 15 minutes, and the mean wheal diameter was
recorded.
Ketotifen dosing
Ketotifen (Novopharm, Toronto, Canada) was initiated
and up-titrated as follows: 1 mg daily for 3 days, 1 mg
twice daily for 4 days, 2 mg twice daily for 7 days, followed
by the initial escalation day. Subjects continued ketotifen
2 mg twice daily on the initial escalation day. Followingthe initial escalation day, ketotifen was maintained at 2 mg
twice daily for 2 weeks, then reduced to 1 mg twice daily
for 2 weeks, then stopped at day +28, based on IRB
approval. If subjects reported side effects such as drow-
siness on ketotifen, the dose was either reduced to the
highest previously tolerated dose, or maintained with-
out dose escalation. Placebo tablets (250 mg lactose tab-
lets, Odan, Montreal, Canada) were administered in the
same manner.
Peanut flour
Premeasured peanut flour (from Partially Defatted Peanut
Flour 12% Fat Light Roast; Golden Peanut Company, Al-
pharetta, Ga; 2 g flour = 1 g peanut protein) doses were
provided to subjects in capsule form. Capsules were taken
intact, not mixed with food, either with or without a meal.
Health Canada approval was obtained for use of this pea-
nut flour capsule in the clinical trial setting.
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The initial escalation day consisted of a one-day (12 hour)
rapid dose escalation, performed using protocol published
previously by Burks et al. [23] slightly modified for the
outpatient setting. Peanut flour capsules were adminis-
tered orally from a starting dose of 0.1 mg peanut protein
in 30 minute intervals until a maximum 25 mg of peanut
protein was tolerated. The maximum dose was modified
to 25 mg rather than 50 mg of peanut protein as the
protocol was performed in an outpatient clinic setting.
Epinephrine, diphenhydramine, cetirizine and salbutamol
were kept at the bedside. An intravenous catheter was
placed prophylactically, vital signs were measured every
30 minutes and subjects were evaluated by the study in-
vestigator before each dose escalation was permitted.Home dosing
Subjects were instructed to take peanut flour doses daily
with food, and were provided with pre-measured cap-
sules. Subjects were instructed to contact the clinic for
dosing instruction with febrile illness or missed doses.Build-up visits
The build-up phase was performed using a previously
published protocol, again slightly modified for the out-
patient setting [9]. Subjects returned to the clinic for
dose escalations every two weeks for 44 weeks. The dose
was increased by 50% at the first visit (total 50 mg
peanut protein), followed by dose increases of 14-33%
thereafter, until a maximum daily maintenance dose of
4000 mg peanut protein was reached.Maintenance phase
At week 44, subjects continued on 4000 mg peanut pro-
tein daily, or their highest tolerated dose, as a mainten-
ance dose for 4 additional weeks.Safety
Subjects were instructed to keep a daily symptom log for
the duration of the study. Subjects were evaluated for
symptoms and adverse reactions based on daily symp-
tom logs every 2 weeks in the clinic. Reaction symptoms
observed in the clinic were graded as 1, 2, or 3, based on
the classification scheme previously published by Brown
[1]. Reaction symptoms from patient diaries were de-
fined as follows; mild: transient and easily tolerated;
moderate: caused discomfort and interrupted the subject’s
usual activities; severe: caused considerable interference
with the subject’s usual activities, was incapacitating or
life-threatening. Anaphylactic reactions were defined as
per the definition of anaphylaxis published by Sampson
et al. in 2006 [24].Results
Study population
Forty subjects were screened from a list of peanut-
sensitized children followed at this outpatient clinic.
Seven children and their parents met inclusion criteria
and consented to participate, one subject withdrew prior
to the start the study for a final enrollment of 6 subjects.
Four subjects were assigned to receive ketotifen pre-
medication, 2 subjects were assigned to receive placebo.
The median age and baseline clinical characteristics were
similar in each group (Table 1).
Ketotifen titration
Ketotifen subjects received a total of 53 days of ketotifen
up-titration and placebo subjects received 28 days of
placebo prior to the initial escalation day. No serious ad-
verse events related to ketotifen were observed. Fatigue
was the major adverse effect noted in the ketotifen
group, occurring only at the highest dose of 2 mg BID,
on 5/25 days (20%) at this dose. Adverse symptoms
reported during up-titration of ketotifen (K) versus pla-
cebo (P) included: fatigue (K: 5 days/53 days, 9%) vs. (P:
0 days/28 days); gastrointestinal symptoms (K: 6 days/
53 days, 11%) vs. (P: 4 days/28 days, 14%); upper respira-
tory tract infection (URTI) (K: 2 days/53 days, 4%) vs.
(P: 2 days/28 days, 7%); along with ongoing pre-existing
seasonal rhinitis and atopic dermatitis. Headache (2 days/
53 days, 4%) and blurred vision with dizziness (1 days/
53 days, 2%) occurred in one ketotifen subject and re-
quired temporary delay in up-titration. At the time of ini-
tial escalation day, all subjects had received 11 to 15 days
of ketotifen premedication and were taking ketotifen 2 mg
twice daily. In the four weeks following the initial escal-
ation day, adverse effects of ketotifen was difficult to inter-
pret, as most adverse effects were related to peanut OIT.
Fatigue, however, was reported in ketotifen subjects on
4 days/118 days (3%), and no placebo subjects. Compli-
ance with ketotifen doses was estimated at 92% (148 tab-
lets taken/161 tablets) prior to initiation of peanut OIT
and 99% (392 tablets taken/394 tablets) during the first
four weeks of peanut OIT. One subject remained on keto-
tifen for a total of 50 days as they were unable to attend
the clinic at the regular visit time. One subject accidentally
continued ketotifen 2 mg bid for 3 weeks, rather than
2 weeks following initial escalation day, then subse-
quently reduced the dose to 1 mg bid for the last week
of ketotifen treatment.
Initial escalation day
The maximum dose of 25 mg peanut protein was reached
by all subjects in the ketotifen and placebo groups. Clinic-
ally relevant symptoms, defined as symptoms suggestive
of an adverse allergic reaction, occurred in 3 of 4 ketotifen
subjects and both placebo subjects (Table 2). Symptoms
Table 1 Baseline clinical characteristics
Clinical characteristic Ketotifen group Placebo group
Number 4 2
Median Age (years) 10 10
Sex 1 female, 3 male 1 female, 1 male
History of asthma 2/4 1/2
History of allergic rhinitis 1/4 0/2
History of atopic dermatitis 2/4 0/2
History of other food allergy 1/4 1/2
Initial median size (mm) of
peanut skin prick test, (range)
10 (7–16) 15 (15)
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protein.
Ketotifen subjects had a lower rate of reaction than
placebo subjects on the initial escalation day. Ketotifen
subjects experienced a lower rate and lower grade of
gastrointestinal symptoms (6/36 doses, 17%, all Grade 1)
than placebo subjects (11/18 doses, 61%; 2/18 Grade 1;
6/18 Grade 2; 3/18 Grade 3). The rate of cutaneous, lower
respiratory and oropharyngeal symptoms was similar in
both groups, and none were of Grade 3 severity. Other
symptoms were reported in placebo patients only and oneTable 2 Adverse reactions to peanut OIT on initial
escalation day (Day 1)
Adverse reactions and treatment Ketotifen Placebo
Total no. of doses of OIT, n 36 18
Total no. of patients reporting symptoms 3/4 2/2
Total no. of doses with symptoms, n
(% of total OIT doses)
8/36 (22%) 12/18 (67%)
Anaphylaxis, n (% of total OIT doses) -* 1 (5%)
Symptoms n, (% of OIT doses) Ketotifen Placebo
Gastrointestinal 6/36 (17%) 11/18 (61%)
Cutaneous - 1/18 (6%)
Lower respiratory 2/36 (6%) 1/18 (6%)
Oropharyngeal - 2/18 (11%)
Upper respiratory - -
Cardiovascular - -
OtherA - 2/18 (11%)
Treatment n, (% of OIT doses) Ketotifen Placebo
Epinephrine - -
Diphenhydramine - -
Cetirizine or other** - 1/18 (6%)
Prednisone - -
Salbutamol or other inhaled medication - 1/18 (6%)
*(−) indicates nil reported.
Aother symptoms reported: Grade 1 headache.
**Other second generation antihistamine.episode of anaphylaxis occurred in the placebo group.
Treatment with antihistamines and inhaled beta agonists
was required in the placebo group only.
Build-up and home doses while on ketotifen (week 0–4)
Both ketotifen and placebo subjects experienced symp-
toms, predominantly gastrointestinal, following most
peanut OIT build up doses (Table 3). The rate of gastro-
intestinal symptoms was similar in both groups. The only
other symptoms reported were cutaneous symptoms in
placebo subjects. Treatment with antihistamines was re-
quired in the ketotifen group only.
Ketotifen subjects had a lower rate of reaction than
placebo subjects after peanut OIT home doses (Table 3).
No peanut OIT home doses were missed among either
group. Ketotifen subjects experienced a lower rate of
gastrointestinal symptoms (50/108 doses, 46%) than pla-
cebo subjects (27/33 doses, 82%). Ketotifen subjects also
experienced a lower rate of cutaneous symptoms (1/108
doses, 1%) than placebo subjects (6/33 doses, 18%). The
rate of lower respiratory, upper respiratory, and oropha-
ryngeal symptoms was similar in both groups. Anaphyl-
axis occurred after home dosing in 1/108 doses (1%)
and 1/33 doses (3%) in ketotifen and placebo patients,
respectively. Treatment for adverse reactions was re-
quired in both the ketotifen (antihistamine and inhaled
beta agonist) and placebo groups (epinephrine, antihis-
tamine, and prednisone).
Build-up, home doses and maintenance off ketotifen
(week 4–44)
Ketotifen subjects had a lower rate of rate of reaction
than placebo subjects following peanut OIT build-up
doses (Table 4). Ketotifen subjects reported a lower rate
of gastrointestinal symptoms (9/61 doses, 15%) than pla-
cebo subjects (15/19 doses, 79%) and a lower rate of re-
spiratory symptoms (2/61 doses, 3%) than placebo subjects
(2/19 doses, 11%). Ketotifen subjects reported a higher rate
of upper respiratory symptoms (4/61 doses, 6%) than pla-
cebo subjects (0/19 doses). The rate of cutaneous and oro-
pharyngeal symptoms was similar, with no anaphylactic
reactions and no treatment required in either group.
Ketotifen subjects had a lower rate of reaction than pla-
cebo subjects following peanut OIT home doses (Table 4).
One peanut OIT home dose was missed in a ketotifen
subject. Ketotifen subjects reported a lower rate of gastro-
intestinal symptoms (95/1221 doses, 8%) than placebo
subjects (83/373 doses, 22%) and a higher rate of upper
respiratory symptoms (55/1221 doses, 5%) than placebo
subjects (0/373 doses). The rate of cutaneous, lower re-
spiratory and oropharyngeal symptoms was similar.
Anaphylaxis occurred after home dosing in 5/1221
(0.4%) of ketotifen subjects, and no placebo subjects.
Treatment for adverse reactions was required in both
Table 3 Adverse reactions to peanut OIT while on Ketotifen (day 2-week 4)
Adverse reactions and treatment Build-up doses in clinic Home doses
Ketotifen Placebo Ketotifen Placebo
Total no. of doses of OIT, n 4 2 108 33
Total no. of missed OIT doses, n - - - -
Total no. of patients reporting symptoms 3 1 4 2
Total no. of doses with symptoms, n (% of OIT doses) 3/4 (75%) 2/2 (100%) 54/108 (50%) 27/33 (82%)
Anaphylaxis, n (% of OIT doses) - - 1/108 (1%) 1/33 (3%)
Symptoms n, (% of OIT doses) Ketotifen Placebo Ketotifen Placebo
Gastrointestinal 3/4 (75%) 2/2 (100%) 50/108 (46%) 27/33 (82%)
Cutaneous - 1/2 (50%) 1/108 (1%) 6/33 (18%)
Lower respiratory - - 6/108 (6%) 2/33 (6%)
Upper respiratory - - 2/108 (2%) -
Oropharyngeal - - 1/108 (1%) -
Cardiovascular - - - -
Other - - 14/108 (13%)B 2/33 (6%)B
Treatment n, (% of OIT doses) Ketotifen Placebo Ketotifen Placebo
Epinephrine - - - 1/33 (3%)
Diphenhydramine - - 1/108 (1%) 1/33 (3%)
Cetirizine** 1/4 (25%) - 7/108 (6%) 5/33 (15%)
Prednisone - - - 1/33 (3%)
Salbutamol or other inhaled medication - - 1/108 (1%) -
BOther reported symptoms included: fever, headache, fatigue, pallor.
**Other second generation antihistamine.
Table 4 Adverse reactions to peanut OIT off ketotifen (week 4–44)
Adverse reactions and treatment Build-up doses in clinic Home doses
Ketotifen Placebo Ketotifen PlaceboC
Total no. of doses of OIT, n 61 19 1221 373
Total no. of missed OIT doses, n - - 1/1221 (.08%) -
Total no. of doses with symptoms, n (% of total OIT doses) 19/61 (31%) 15/19 (79%) 156/1221 (13%) 97/373 (26%)
Anaphylaxis, n (% of total OIT doses) - - 5/1221 (0.4%) -
Symptoms n, (% of OIT doses) Ketotifen Placebo Ketotifen Placebo
Gastrointestinal 9/61 (15%) 15/19 (79%) 95/1221 (8%) 83/373 (22%)
Cutaneous - - 12/1221 (0.9%) 15/373 (4%)
Lower respiratory 2/61 (3%) 2/19 (11%) 23/1221 (2%) 12/373 (3%)
Upper respiratory 4/61 (6%) - 55/1221 (5%) -
Oropharyngeal 2/61 (3%) - 12/1221 (0.9%) -
Cardiovascular - - - -
Other 8/61 (13%) - 122/1221 (10%)D 12/373 (3%)D
Treatment n, (% of OIT doses) Ketotifen Placebo Ketotifen Placebo
Epinephrine - - 1/1221 (0.08%) -
Diphenhydramine - - 11/1221 (0.9%) -
Cetirizine** - - 44/1221 (4%) 1/373 (0.2%)
Prednisone - - 2/1221 (0.1%) -
Salbutamol or other inhaled medication - - 27/1221 (2%) 9/373 (2%)
COne placebo subject withdrew during the initial 4 weeks of peanut OIT and therefore was not included in these results.
DOther reported symptoms/adverse effects included: atopic dermatitis, headache, gastroenteritis, pinworms, seasonal allergic rhinitis, strep throat and URTI.
**Other second generation antihistamine.
Jagdis et al. Allergy, Asthma & Clinical Immunology 2014, 10:36 Page 6 of 9
http://www.aacijournal.com/content/10/1/36
Jagdis et al. Allergy, Asthma & Clinical Immunology 2014, 10:36 Page 7 of 9
http://www.aacijournal.com/content/10/1/36the ketotifen (epinephrine, antihistamine, prednisone,
inhaled beta agonists) and placebo groups (antihistamine,
inhaled beta agonists).
Anaphylaxis
In total, 8 episodes of anaphylaxis were reported, 6 in
ketotifen subjects and 2 in placebo subjects. The overall
incidence of anaphylaxis per dose of peanut OIT was 6/
1430 (0.4%) in ketotifen subjects and 2/445 (0.4%) for
placebo subjects. Epinephrine was used for treatment of
only two anaphylactic reactions. Symptoms of anaphylaxis
included: cutaneous (8/8), lower respiratory (7/8), upper
respiratory (3/8), oropharyngeal (6/8), gastrointestinal (5/
8), cardiovascular (0/8). Anaphylaxis after home doses oc-
curred in the presence of known cofactors including: fever/
infection (2/7), exercise (4/7) and menstruation (1/7).
Study withdrawal
One subject withdrew prior to the start of the study and
therefore was not included in the analysis. One placebo
subject withdrew from the study on day 7, and one ketoti-
fen subject withdrew in week 36, both following an ana-
phylactic reactions requiring emergency room treatment.
Final dose and peanut specific IgE
Three ketotifen subjects and one placebo subject com-
pleted the 44 week peanut OIT protocol. The median
dose of peanut protein that elicited symptoms on initial
escalation day was 200 mcg. For subjects completing pea-
nut OIT, the median dose of peanut protein tolerated was
1825 mg for both the ketotifen and placebo subject(s).
Subjects were then dose adjusted to receive ongoing
maintenance with either whole roasted peanut, or peanut
M&M’s®, per subject preference. The first dose of whole
peanut or M&M’s® was administered in the clinic in a
monitored setting. The median peanut specific IgE was 84
kUA/L at completion of peanut OIT (median 69 kUA/L in
ketotifen subjects; >100 kUA/L in the placebo subject).
Discussion
Although early studies of peanut OIT appear to show
promise in inducing desensitization [8,9], the frequency
and severity of adverse allergic reactions during peanut
OIT remain a concern. The highest reported rates of ad-
verse allergic reactions in peanut OIT have typically been
during periods of rapid dose escalation [8]. In this small
proof of concept study, we examined the use of ketotifen
premedication during the initial 4 weeks of peanut OIT.
The present study was limited by the small number of
patients and short duration. Statistical analysis was not
feasible given the small numbers, which prevents us
from drawing firm conclusions. However, this work was
performed as a pilot study, and requires confirmation ina larger scale study of ketotifen premedication used
throughout OIT.
All subjects experienced clinically relevant adverse
symptoms at some point during peanut OIT, in keeping
with other reports of peanut OIT using similar proto-
cols [9,23]. Subjects receiving ketotifen premedication
had a lower frequency and severity of reactions on the
initial escalation day and during the first four weeks of
peanut OIT than subjects receiving placebo. This was in
large part due to a reduction in gastrointestinal reac-
tions. Gastrointestinal (GI) symptoms were the most
frequently reported clinically relevant symptoms on the
initial escalation day and, in fact, throughout the duration
of peanut OIT. In contrast, in a previous safety study of a
similar peanut OIT regimen, upper respiratory symptoms
were the most common, and gastrointestinal symptoms
were considerably less frequent during home doses [11]. A
lower overall frequency of GI symptoms and, in particular,
a lower frequency of moderate to severe GI symptoms
was observed in subjects receiving ketotifen premedica-
tion. In eosinophilic gastroenteritis, which may not be
analogous to food OIT, ketotifen treatment has been asso-
ciated with symptomatic and histologic improvement [16].
The postulated mechanisms behind its efficacy include
H1-antihistamine activity, stabilization of mast cells, and
possibly impairment of eosinophil migration [16,25]. In
our study, the trend of reduced GI symptoms appeared to
persist in the ketotifen subjects after ketotifen was discon-
tinued. There is one case report describing prolonged re-
mission of eosinophilic gastroenteritis after one month of
ketotifen treatment [25]. However, given the small
number of study subjects, individual variation in suscep-
tibility to GI symptoms, viral gastroenteritis and other
causes of transient GI upset are likely to have influenced
our results.
Lower respiratory symptoms were experienced at simi-
lar frequency between both groups during the initial es-
calation day, home doses and build-up doses. Asthmatic
subjects were included in both groups, and moderate to
severe lower respiratory symptoms were rare. Ketotifen
is known to have a delayed onset of action in asthma, tak-
ing up to 6–12 weeks to achieve maximal response [14].
Therefore our six week trial of ketotifen may have been
insufficient to detect any effect on lower respiratory reac-
tions, particularly during the initial dose escalation day
which was performed after two weeks of ketotifen pre-
medication. In addition, the small number of subjects and
the relative infrequency of lower respiratory reactions
would make it difficult to detect a difference.
Upper respiratory symptoms were predominantly re-
ported with home doses after ketotifen was discontinued,
and therefore may have initially been suppressed by the
H1-antihistamine activity of ketotifen. However, these re-
sults were also likely influenced by other common causes
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fection and sinusitis. One ketotifen subject had allergic
rhinitis prior to starting peanut OIT and required treat-
ment with Cetirizine for approximately seven weeks after
ketotifen was discontinued which likely influenced the
adverse effects reported by this patient. Oropharyngeal
symptoms were relatively uncommon in both groups,
and no cardiovascular symptoms were reported.
Cutaneous symptoms were rarely reported while on
ketotifen premedication, again suggesting suppression by
the H1 antihistamine activity of ketotifen. This raises the
issue of potential “masking” or partial treatment of a
reaction by ketotifen premedication leading to under-
recognition of a reaction by patients or their parents.
This is concerning as many patients recognize cutaneous
symptoms as key initial symptoms of reaction. Additional
safety studies are required before premedication can be
recommended during oral immunotherapy for food al-
lergy. However, if premedication is used in future OIT
research, patients should be educated on recognition of
atypical presentations of anaphylaxis.
Eight episodes of anaphylaxis occurred, all involving
cutaneous symptoms, and the majority occurring after
home doses taken in the context of known cofactors of
anaphylaxis. As a result of anaphylactic reactions, one
subject from each of the ketotifen and placebo groups
withdrew from the study. Accidental peanut ingestion
and accidental overdose of peanut OIT were not observed
but remain relevant concerns. Despite education, epineph-
rine was used in only two cases of anaphylaxis. The on-
going risk of anaphylaxis with home doses of peanut OIT
should be emphasized to patients, particularly in the set-
ting of cofactors of anaphylaxis, and patients should be
prepared to treat reactions should they occur.
As ketotifen was continued for only the first four weeks
of OIT, we cannot predict whether ongoing ketotifen pre-
medication would have reduced frequency and severity of
adverse reactions experienced during the remainder of
peanut OIT. For the same reason, we cannot predict
whether the use of ketotifen premedication would have
influenced the efficacy of peanut OIT. At the end of the
study, the remaining placebo and ketotifen patient(s) tol-
erated equivalent median doses of peanut protein.
Oral immunotherapy is a promising area of investigation
for treatment of peanut and other food allergy. However,
safety concerns remain regarding the frequency and se-
verity of adverse reactions during peanut OIT, particu-
larly during periods of rapid dose escalation [8]. Our
findings suggest that ketotifen premedication is well
tolerated and reduces frequency and severity of gastro-
intestinal adverse reactions during peanut OIT. Larger
randomized studies of the safety and efficacy of pre-




The authors declare that they have no competing interests.
Authors’ contributions
AJ wrote the manuscript. GS conceived of the study, participated in the
design and coordination of the study, and revised the manuscript. NB, MG,
NL and SM, participated in coordination of the study and data collection. CB
participated in data collection. All authors read and approved the final
manuscript.
Acknowledgements
We gratefully acknowledge Dennis Penn from Mast Cell Pharmaceuticals,
and Nancy Amos for their assistance.
This study was performed with approval by Canadian Shield Ethics Board.
Author details
1Division of Clinical Immunology and Allergy, Department of Medicine,
University of Toronto, 202 St Clair Ave W, Toronto, ON M4V 1R2, Canada.
2Faculty of Medicine, University of Toronto, Toronto, ON, Canada. 3Gordon
Sussman Clinical Research Inc., Toronto, ON, Canada. 4Melbourne Medical
School, University of Melbourne, Melbourne, Australia. 5Faculty of Medicine,
University of Ottawa, Ottawa, ON, Canada.
Received: 7 April 2014 Accepted: 27 June 2014
Published: 9 July 2014
References
1. Sicherer SH, Muñoz-Furlong A, Godbold JH, Sampson HA: US prevalence of
self-reported peanut, tree nut, and sesame allergy: 11-year follow-up.
J Allergy Clin Immunol 2010, 125, 6:1322–1326.
2. Fleischer DM, Conover-Walker MK, Christie L, Burks AW, Wood RA: The
natural progression of peanut allergy: resolution and the possibility of
recurrence. J Allergy Clin Immunol 2003, 112, 1:183–189.
3. Neuman-Sunshine DL, Eckman JA, Keet CA, Matsui EC, Peng RD,
Lenehan PJ, Wood RA: The natural history of persistent peanut allergy.
Ann Allergy Asthma Immunol 2012, 108, 5:326–331.
4. Bock SA, Muñoz-Furlong A, Sampson HA: Fatalities due to anaphylactic
reactions to foods. J Allergy Clin Immunol 2001, 107, 1:191–193.
5. Flokstra-de Blok BMJ, Dubois AE, Vlieg-Boerstra BJ, Oude Elberink JN, Raat H,
DunnGalvin A, Hourihane JO, Duiverman EJ: Health-related quality of life
of food allergic patients: comparison with the general population and
other diseases. Allergy 2010, 65:238–244.
6. Nelson HS, Lahr J, Rule R, Bock A, Leung D: Treatment of anaphylactic
sensitivity to peanuts by immunotherapy with injections of aqueous
peanut extract. J Allergy Clin Immunol 1997, 99, 6, Pt 1:744–751.
7. Oppenheimer JJ, Nelson HS, Bock SA, Christensen F, Leung DY: Treatment
of peanut allergy with rush immunotherapy. J Allergy Clin Immunol 1992,
90, 2:256–262.
8. Sheikh A, Nurmatov U, Venderbosch I, Bischoff E: Oral immunotherapy for
the treatment of peanut allergy: systematic review of six case series
studies. Prim Care Respir J 2013, 21, 1:41–49.
9. Varshney P, Jones SM, Scurlock AM, Perry TT, Kemper A, Steele P, Hiegel A,
Kamilaris J, Carlisle S, Yue X, Kulis M, Pons L, Vickery B, Burks AW: A
randomized controlled study of peanut oral immunotherapy: clinical
desensitization and modulation of the allergic response. J Allergy Clin
Immunol 2011, 127, 3:654–660.
10. Nurmatov U, Venderbosch I, Devereux G, Simons FE, Sheikh A:
Allergen-specific oral immunotherapy for peanut allergy. Cochrane
Database Syst Rev 2013, 12, 9:CD009014.
11. Hofmann AM, Scurlock AM, Jones SM, Palmer KP, Lokhnygina Y, Steele PH,
Kamilaris J, Burks AW: Safety of a peanut oral immunotherapy protocol in
children with peanut allergy. J Allergy Clin Immunol 2009, 124, 2:286–291.
12. Brockow K, Kiehn M, Riethmüller C, Vieluf D, Berger J, Ring J: Efficacy of
antihistamine pretreatment in the prevention of adverse reactions to
Hymenoptera immunotherapy: a prospective, randomized,
placebo-controlled trial. J Allergy Clin Immunol 1997, 100, 4:458–463.
13. Müller UR, Jutel M, Reimers A, Zumkehr J, Huber C, Kriegel C, Steiner U,
Haeberli G, Akdis M, Helbling A, Schnyder B, Blaser K, Akdis C: Clinical and
Jagdis et al. Allergy, Asthma & Clinical Immunology 2014, 10:36 Page 9 of 9
http://www.aacijournal.com/content/10/1/36immunologic effects of H1 antihistamine preventive medication during
honeybee venom immunotherapy. J Allergy Clin Immunol 2008,
122, 5:1001–1007.
14. MacDonald GF: An overview of ketotifen. Chest 1982, 82:30S–32S.
15. Kabra SK, Pandey RM, Singh R, Seth V: Ketotifen for asthma in children
aged 5 to 15 years: a randomized placebo-controlled trial. Ann Allergy
Asthma Immunol 2000, 85, 1:46–52.
16. Melamed I, Feanny SJ, Sherman PM, Roifman CM: Benefit of ketotifen in
patients with eosinophilic gastroenteritis. Am J Med 1991, 90, 3:310–314.
17. Czarnetzki BM: A double-blind, crossover study of the effect of ketotifen
in urticaria pigmentosa. Dermatologica 1983, 166:44–47.
18. St-Pierre JP, Kobric M, Rackham A: Effect of ketotifen treatment on
cold-induced urticaria. Ann Allergy 1985, 55, 6:840–843.
19. Abelson MB, Chapin MJ, Kapik BM, Shams NB: Efficacy of ketotifen fumarate
0.025% ophthalmic solution compared with placebo in the conjunctival
allergen challenge model. Arch Ophthalmol 2003, 121, 5:626–630.
20. Berdy GJ, Spangler DL, Bensch G, Berdy SS, Brusatti RC: A comparison of
the relative efficacy and clinical performance of olopatadine
hydrochloride 0.1% ophthalmic solution and ketotifen fumarate 0.025%
ophthalmic solution in the conjunctival antigen challenge model.
Clin Ther 2000, 22, 7:826–833.
21. Kettelhut BV, Berkebile C, Bradley D, Metcalfe DD: A double-blind,
placebo-controlled, crossover trial of ketotifen versus hydroxyzine in
the treatment of pediatric mastocytosis. J Allergy Clin Immunol 1989,
83, 5:866–870.
22. Schwarzer G, Bassler D, Mitra A, Ducharme FM, Forster J: Ketotifen alone or
as additional medication for long-term control of asthma and wheeze in
children. Cochrane Database Syst Rev 2004, 1:CD001384.
23. Jones SM, Pons L, Roberts JL, Scurlock AM, Perry TT, Kulis M, Shreffler WG,
Steele P, Henry KA, Adair M, Francis JM, Durham S, Vickery BP, Zhong X,
Burks AW: Clinical efficacy and immune regulation with peanut oral
immunotherapy. J Allergy Clin Immunol 2009, 124, 2:292–300.
24. Sampson HA, Munoz-Furlong A, Campbell RL, Adkinson NF Jr, Bock SA,
Branum A, Brown SG, Camargo CA Jr, Cydulka R, Galli SJ, Gidudu J,
Gruchalla RS, Harlor AD Jr, Hepner DL, Lewis LM, Lieberman PL,
Metcalfe DD, O'Connor R, Muraro A, Rudman A, Schmitt C, Scherrer D,
Simons FE, Thomas S, Wood JP, Decker WW: Second symposium on the
definition and management of anaphylaxis: summary report—
Second National Institute of Allergy and Infectious Disease/Food Allergy
and Anaphylaxis Network symposium. J Allergy Clin Immunol 2006,
117:391–397.
25. Bolukbas FF, Bolukbas C, Uzunkoy A, Baba F, Horoz M, Ozturk E: A dramatic
response to ketotifen in a case of eosinophilic gastroenteritis mimicking
abdominal emergency. Dig Dis Sci 2004, 49, 11–12:1782–1785.
doi:10.1186/1710-1492-10-36
Cite this article as: Jagdis et al.: Effect of ketotifen premedication on
adverse reactions during peanut oral immunotherapy. Allergy, Asthma &
Clinical Immunology 2014 10:36.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
